JP MORGAN/CALL/MEDTRONIC/85/0.1/15.11.24 Share Price

Warrant

DE000JK4L7T2

Market Closed - Bid/Ask 14:42:35 04/07/2024 BST Pre-market 07:00:19
0.12 EUR -7.69% Intraday chart for JP MORGAN/CALL/MEDTRONIC/85/0.1/15.11.24 0.145 +20.83%
Current month-29.41%
1 month-63.64%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
04/07/24 0.12 -7.69%
03/07/24 0.13 0.00%
02/07/24 0.13 -23.53%
01/07/24 0.17 0.00%
28/06/24 0.17 -10.53%

Delayed Quote Börse Stuttgart

Last update July 04, 2024 at 02:42 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying MEDTRONIC PLC
Issuer J.P. Morgan
WKN JK4L7T
ISINDE000JK4L7T2
Date issued 19/03/2024
Strike 85 $
Maturity 15/11/2024 (134 Days)
Parity 10 : 1
Emission price 0.54
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 0.71
Lowest since issue 0.12
Spread 0.03
Spread %18.75%

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
77.17 USD
Average target price
94.02 USD
Spread / Average Target
+21.84%
Consensus